Bicara Therapeutics Inc. Common Stock (BCAX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$23.09
Price Target
$20.00
Target Range
$14.00 — $28.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-18.5x
Forward PEG—
Implied Growth-22.6%
Median Target$18.00
Analyst Spread70.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$14
-39.4%
Consensus
$20
-13.4%
Bull Case
$28
+21.3%
BCAX Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Bicara Therapeutics Inc. Common Stock (BCAX) has a Wall Street consensus price target of $20.00, based on estimates from 6 covering analysts. With the stock currently trading at $23.09, this represents a potential downside of -13.4%. The company has a market capitalization of $1.26B.
Analyst price targets range from a low of $14.00 to a high of $28.00, representing a 70% spread in expectations. The median target of $18.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BCAX trades at a trailing P/E of -18.5x. Analysts expect EPS to grow -22.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+53.2%
Avg Forward P/E17.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 TGTXTG Therapeutics, Inc. | $6.9B | $43.02 | $39.00 | -9.4% | Buy | 32.3x | 13 |
 ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
 ERASErasca, Inc. | $3.0B | $10.40 | $13.60 | +30.8% | Buy | — | 11 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 MGNXMacroGenics, Inc. | $186M | $2.94 | $6.00 | +104.1% | Buy | — | 22 |
 XNCRXencor, Inc. | $903M | $12.31 | $32.33 | +162.6% | Buy | — | 27 |
 ALKSAlkermes plc | $5.9B | $35.40 | $44.00 | +24.3% | Buy | — | 28 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 AGENAgenus Inc. | $132M | $3.75 | $7.33 | +95.5% | Buy | 1.8x | 11 |
Upside Potential Comparison
XNCRMGNXAGENIMVTKYMRERASALKSRCUSSee BCAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCAX — Frequently Asked Questions
Quick answers to the most common questions about buying BCAX stock.
What is the BCAX stock price target for 2026?
BCAX's consensus price target is $20, -13.4% below the current price of $23.09. The 6 analysts tracking BCAX see downside risk at present valuations.
Is BCAX a buy, sell, or hold?
BCAX has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $20 implies -13.4% downside from current levels.
Is BCAX stock overvalued or undervalued?
BCAX's current price is $23.09 with a consensus target of $20 (-13.4% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can BCAX stock go?
The most bullish Wall Street analyst has a price target of $28 for BCAX, while the most conservative target is $14. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BCAX stock?
BCAX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BCAX stock forecast?
The 12-month BCAX stock forecast based on 6 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $14 (bear case) to $28 (bull case). The median consensus rating is "Buy".
Should I buy BCAX stock?
Analysts are cautious on BCAX, with 0 Sell ratings and a price target of $20 (-13.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BCAX price targets vary so much?
BCAX analyst price targets range from $14 to $28, a 70% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.